Medindia
Medindia LOGIN REGISTER
Advertisement

Tress Capital Makes Strategic Investment in iCAN, an Israeli Cannabis Innovator

Monday, December 9, 2019 Drug News
Advertisement
NEW YORK and TEL AVIV, Israel, Dec. 9, 2019 /PRNewswire/ -- iCAN Israel-Cannabis and Tress Capital are thrilled to announce a strategic investment by Tress into iCAN.
Advertisement

Tress's investment will align its mostly North American strategic cannabis investments with that of iCAN, an international cannabis incubator corporation based in Israel. The companies are working on joint strategic initiatives that create an unmatched global canvas of cannabis industry coverage and capabilities.
Advertisement

Saul Kaye, CEO of iCAN, stated: "Tress was our first global sponsor at CannaTech Tel Aviv six years ago and have partnered with us every year since. I am extremely proud to have announced at the recently held CannaTech Cape Town event, an investment by Tress into iCAN and I know that together we will continue to build this global cannabis ecosystem. Tress's robust portfolio of cannabis technology companies in North America together with iCAN's strong IP and Israel-focused portfolio will create synergies and drive expansion for our companies. The CannaTech Cape Town event brought together the best Cannabis minds from around the world to build and create amazing opportunities for the African Continent."

Asher Troppe and David Hess, Co-founders at Tress Capital added: "We are proud to be long-term sponsors of CannaTech and to advance our relationship with a strategic investment in iCAN. Saul and his team have always had their finger on the pulse of the global cannabis ecosystem and like us support Israel's continued leadership in the medical and technology-based cannabis markets. This deal also enables our organizations to explore leveraging key resources to create truly peerless global capabilities and opportunities for our clients, portfolio companies, and shareholders. Tress and iCAN both believe in a responsible approach to the rollout of the cannabis industry, and working together we will continue to lead in this mission globally."

The investment funds will be used to grow the global CannaTech footprint and incubate cannabis-related businesses.

ZAG-SW and Shwergold Aharonson & Co. acted as legal advisor to iCAN, while Tress Capital was advised by Goldfarb Seligman.

About iCAN: Israel-Cannabis

iCAN: Israel-Cannabis is building the Global Cannabis Ecosystem. iCAN is committed to accelerate Israel's Canna-Technology industry, capitalizing on Israeli innovation and a leading cannabis regulatory environment to bring premier products to market. iCAN is powered by CannaTech, the premier international cannabis summit held annually in Tel Aviv, and around the world, including London, Sydney, Hong Kong, Panama, and now Cape Town. In 2020, CannaTech will be in Davos, Switzerland, China and Tel Aviv.

About CannaTech

CannaTech is the only Medical Cannabis event of its kind with a global focus that offers senior industry leaders, medical and scientific experts, and new ventures the platform to come together, drive innovation, form partnerships and promote knowledge exchange.

About Tress Capital

Tress Capital, one of the first private equity firms dedicated to cannabis, serves family-office, high net worth, and institutional clients. For updates on the Company's activities and highlights of the Company's press releases, portfolio, and other media coverage, please visit Tress's web site at www.tresscapital.com. Tress Solutions provides business development, strategy, and operational support to sector companies.

Media Inquiries: [email protected] +972-54-806-8613iCan Investor Inquiries: [email protected] +972-54-560-4843Tress Inquiries: [email protected]

 

Cision View original content:http://www.prnewswire.com/news-releases/tress-capital-makes-strategic-investment-in-ican-an-israeli-cannabis-innovator-300971242.html

SOURCE iCAN; Tress Capital

Sponsored Post and Backlink Submission


Latest Press Release on Drug News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close